Orchid Pharma Limited has informed the Exchange regarding 'Update on purchase of Assets of Allecra Therapeutics SAS'.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma Limited has received approval from the French Court to acquire the assets of Allecra Therapeutics SAS, effective August 01, 2025. This is an update to the company's earlier intimation dated July 30, 2025, regarding the asset purchase. Allecra Therapeutics is a France-based pharmaceutical company, and the involvement of a French court suggests the acquisition is being executed through a judicial or insolvency process. With the court order now in favor of Orchid Pharma, the company can formally proceed to take over Allecra's assets. The deal expands Orchid Pharma's asset base in the specialty pharmaceuticals space, though financial terms and the exact nature of assets being acquired were not disclosed in this filing.
Positive for shareholders as the acquisition strengthens Orchid Pharma's product portfolio and pipeline, potentially adding new therapeutic assets and IP from Allecra Therapeutics. The court approval removes a key legal hurdle and signals that the deal is now moving forward for completion.